Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that its lead compound, BGB324 has potential application as a novel treatment for non-small cell lung cancer (NSCLC) was presented in a poster at the American Association of Cancer Research and The International Association for the Study of Lung Cancer's (AACR-ISLAC) joint conference on the Molecular Origins of Lung Cancer, which took place on January 6-9, 2014.1
The study was conducted in collaboration with investigators at the University of Bergen and University of Texas Southwestern Medical Center in Dallas and highlights the potential of BGB324, a first-in-class, highly selective small molecule inhibitor of the Axl receptor tyrosine kinase, as a novel therapeutic option for NSCLC.
The study evaluated the effects of BGB324 on NSCLC cells in in vitro 3D assays and in mouse xenograft models, in combination with targeted chemotherapeutic agents. The results demonstrated that BGB324 can overcome acquired drug resistance in in vivo models of NSCLC and suggests that BGB324 may be effective in treating patients with drug-resistant NSCLC, caused by long-term use of the EGFR inhibitor erlotinib (Roche's Tarceva), the current first line treatment for EGFR mutated NSCLC patients. The results also demonstrated that treatment with BGB324 could enhance the antitumor activities of chemotherapeutic and targeted agents such as docetaxel and bevacizumab (Sanofi's Taxotere and Roche's Avastin) in patients with NSCLC.
BGB324 is the only selective Axl inhibitor in clinical development having recently completed a phase Ia clinical trial. Phase Ib clinical trials are planned in acute myeloid leukemia and NSCLC in 2014.
Professor James Lorens, Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Norway and Chief Scientific Officer and co-founder of BerGenBio, commented: "The results presented in this poster support our view that targeting Axl is a promising new approach to treating drug resistant cancers. There is an urgent unmet medical need for new therapies that are able to overcome drug resistance, particularly in non-small cell lung cancer. This data suggests that BGB324 has the potential to do this and we look forward to exploring this further in the clinic."
1. Katarzyna Wnuk-Lipinska, Gro Gausdal, Tone Sandal et al. Selective Small Molecule AXL Inhibitor BGB324 Overcomes Acquired Drug Resistance in Non-Small Cell Lung Carcinoma Models, AACR-ISLAC joint conference on the Molecular Origins of Lung Cancer, January 6-9, 2014.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Lung Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
AS, BerGenBio. "BerGenBio presents data at AACR-ISLAC conference on the molecular origins of lung cancer." Medical News Today. MediLexicon, Intl., 13 Jan. 2014. Web.
10 Mar. 2014. <http://www.medicalnewstoday.com/releases/271086>
AS, B. (2014, January 13). "BerGenBio presents data at AACR-ISLAC conference on the molecular origins of lung cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271086.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.